As of this writing, NIAID and industry collaborators are also finalizing the design of a large-scale trial to assess whether COVID-Ig can reduce the rate of hospitalization and other medical encounters in earlier-stage COVID-19 patients exhibiting mild to moderate symptoms.
Studies shed light on whether high-dose intravenous immune globulin, convalescent plasma and hyperimmune globulin will be effective therapeutic options for the novel coronavirus.
Is SCIG well-accepted by most patients either previously treated with IVIG or just starting out on IG therapy?
This extremely rare disease affects mostly younger adults, and its cause remains a mystery.
Optimism continues to grow about the use of stem cells in regenerative medicine highlighted by hundreds of successful clinical trials.
Social media continues to shape and influence the evolving healthcare landscape.
With the growing number of healthcare apps, patients and providers need to be aware of their benefits, as well as their shortfalls that could affect patient care.
Some promising new methods for delivering vaccinations could mean a pain-free alternative, the elimination of accidental needlesticks and reduced risk of infections.
Social media platforms have given the anti-vaccine faction a significant voice that has undermined advances in public health. Now, in the wake of a global pandemic, healthcare stakeholders may have an opportunity to reclaim the narrative about vaccines with facts, not fiction.
While vaccination rates in the U.S. are rising, they are still too low among all age groups.
For decades, scientists have discussed the concept of a “universal” flu vaccine that could provide broad protection against seasonal and pandemic influenza viruses, and we now have a number of promising vaccine candidates with a realistic chance to fulfill the dream.
Dispelling the many popular myths surrounding this chronic painful disorder that afflicts millions of people will ensure patients can get the treatment they need.
